Acquired Factor X Deficiency in a Patient with Amyloidosis

Summary

A patient with extensive amyloidosis and a selective factor X deficiency is described. The following observations indicate that the factor X deficiency in this case is not inherited.

1. The first symptoms of a bleeding tendency appeared at an age of 50 years.

2. The patient’s four children had no clotting defect.

3. After infusion of 1 liter of fresh plasma no increased factor X activity was observed. No anticoagulants could be demonstrated in vitro.

• References

• 1 Aas K. Prokonvertin og konvertin. Thesis. Akad. Trykkningssentralen; Oslo: 1952
• 2 Bell W. N, Alton H. B. Christmas disease associated with factor VII deficiency: case report with family survey. Brit. med. J 1955; 1: 330
• 3 Björkman S. E. A new method for enumeration of platelets. Acta haemat. (Basel) 1959; 22: 377
• 4 Blombäck B. On the properties of fibrinogen and fibrin. Ark. Kemi 1958; 12: 99
• 5 Castleman B, Kibbee B. V. Case records. New Engl. J. Med 1960; 263: 647
• 6 Crockett C. L, Shotton D, Craddock C. G, Leavell B. S. Hypoprothrombinemia: Studies of a case of the idiopathic type and the effect of serum administration. Blood 1949; 4: 1298
• 7 Denson W. W. Electrophoretic studies of the Prower factor: a blood coagulation factor which differs from factor VII. Brit. J. Haematol 1958; 4: 313
• 8 Duckert F. On the properties of the Stuart-Prower factor. Thromb. Diath. haem. (suppl.) 1960; 4: 32
• 9 Egeberg O. Assay of antihaemofilic AB, and C factors by one-stage cephalin systems. Scand. J. clin. Eab. Invest 1961; 13: 140
• 10 Gelin L. E, Korsan-Bengtsen K, Ygge J, Zederfeldt B. Influence of low viscous dextran on the hemostatic mechanism. Acta chir. scand 1961; 122: 324
• 11 Graham J. B. Stuart clotting defect and Stuart factor. Thromb. Diath. haem. (suppl.) 1961; 4: 22
• 12 Graham J. B, Barrow E. M, Haugie C. Stuart clotting defect II. Genetic aspects of a "new" hemorrhagic state. J. clin. Invest 1957; 36: 497
• 13 Hasselback R, Hjort P. F. Effect of heparin on in vivo turnover of clotting factors. J. appl. Physiol 1960; 15: 945
• 14 Hjort P, Rapaport S. I, Owren P. A. A simple specific one-stage prothrombin assay using Russell's viper venom in cephalin suspension. J. Lab. clin. Med 1955; 46: 89
• 15 Hougie C, Barrow E. M, Graham J. B. Stuart clotting defect, I. Segregation of an hereditary hemorrhagic state from the heterogenous group heretofore called "Stable Factor" (SRCA, Proconvertin, Factor VII) deficiency. J. clin. Invest 36: 485 1957;
• 16 Ivy A. C, Shapiro P. E, Melnick P. Bleeding tendency in jaundice. Surg. Gynec. Obstet 1935; 60: 781
• 17 Kaulla K. N. von. Intravenous protein-free pyrogen: a powerful fibrinolytic agent in man. Circulation 1958; 17: 187
• 18 Owren P. A. The coagulation of blood. Investigation on a new clotting factor. Thesis. Acta med. Scand Suppl 128: 194 1947;
• 19 Owren P. A, Aas K. The control of dicoumarol therapy and the quantitative deter-mination of prothrombin and proconvertin. Scand. J. clin. Lab. Invest 1951; 3: 201
• 20 Quick A. J, Stanley-Broman M, Bancroft F. W. A study of the coagulation defect in hemophilia and in jaundice. Am. J. med. Sci 1935; 190: 501
• 21 Rabiner S. F, Kretchmer N. The Stuart-Prower factor: utilization of clotting factors obtained by Starch-Block electrophoresis for genetic evaluation. Brit. J. Haemat 1961; 7: 99
• 22 Roos J, Arkel van C, Verloop M. C, Jordan F. L. J. A "new" family with Stuart-Prower deficiency. Thromb. Diath. haem 1959; 3: 59
• 23 Rukavina J. G, Block W. D, Jackson C. E, Fall H. F, Carey J. H, Curtis A. C. Primary systemic amyloidosis: a review and an experimental genetic, and clinical study of 29 cases with particular emphasis on the familial forms. Medicine 1956; 35: 239
• 24 Telfer T. P, Denson K. W, Wright D. R. A "new" coagulation defect. Brit. J. Haemat 1956; 2: 308
• 25 Waaler B. Contact activation in the intrinsic blood clotting system. Studies on a plasma product formed on contact with glass and similar surfaces. Thesis. Scand. J. clin. Lab. Invest. (suppl.) 1959; 11: 37